Garcinol / Casp3 Cancer Research Results

Garcinol — a naturally occurring polyisoprenylated benzophenone and polycyclic polyprenylated acylphloroglucinol isolated principally from the dried fruit rind of Garcinia indica, commonly called kokum. It is an experimental phytochemical and pleiotropic epigenetic/signalling modulator, abbreviated GAR and also known as camboginol. Garcinol is best characterized as an inhibitor of lysine and histone acetyltransferases, particularly p300/CBP and PCAF/KAT2B, while also modulating NF-κB, STAT3, PI3K/AKT, inflammatory lipid mediators, apoptosis, and epithelial–mesenchymal plasticity. It is not an approved anticancer drug and should not be equated with whole Garcinia cambogia or hydroxycitric-acid supplements.

Primary mechanisms (ranked):

1. Inhibition of p300/CBP and PCAF histone acetyltransferase activity, producing broad changes in histone and non-histone protein acetylation, chromatin transcription, DNA-damage responses, and oncogenic gene expression.
2. Suppression of NF-κB and JAK/Src/STAT3 survival and inflammatory transcription, with reductions in Bcl-2-family proteins, survivin, cyclin D1, VEGF, cytokines, and invasion-associated genes.
3. Induction of intrinsic and extrinsic apoptosis through mitochondrial membrane-potential loss, cytochrome-c release, Bax/Bcl-2 displacement, caspase activation, DR5 upregulation, and c-FLIP/XIAP suppression.
4. Suppression of PI3K/AKT/mTOR, FAK/Src/ERK, Wnt/β-catenin, Notch, and cancer-stem-cell signalling in model-dependent settings.
5. Reversal of epithelial–mesenchymal transition and inhibition of invasion, migration, angiogenesis, and stem-like phenotypes through modulation of E-cadherin, vimentin, ZEB factors, Twist1, MMP-2/9, miR-200-family members, let-7, and related pathways.
6. Inhibition of inflammatory lipid-mediator enzymes, including 5-lipoxygenase and microsomal prostaglandin E synthase-1, reducing leukotriene and PGE2-associated signalling.
7. ROS elevation and oxidative-stress-mediated apoptosis in selected cancer models; this is secondary and context-dependent because garcinol can also act as a direct antioxidant or radical scavenger in cell-free and non-cancer systems.
8. Chemosensitization and radiosensitization through suppression of survival and EMT pathways and, for radiation, inhibition of p300/CBP-dependent non-homologous end joining.

Bioavailability / PK relevance: Garcinol is highly lipophilic and poorly water-soluble, making oral absorption and formulation important translational variables. Rat studies reported approximately 27–36% absolute oral bioavailability at oral doses of 22.5–45 mg/kg, with dose-dependent exposure and substantial tissue distribution. Human liver-microsome data suggest intermediate metabolic clearance, but no validated human cancer PK, therapeutic plasma range, or clinically established dose is available. Nanoparticles, phospholipid complexes, cyclodextrins, and other delivery systems may improve exposure, but remain preclinical.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 5–50 µM garcinol, frequently around 10–25 µM. Whether these free concentrations are safely achievable in human tumors is unknown. Rat PK indicates systemic absorption, but it does not establish sustained human exposure comparable with common cell-culture concentrations. Results obtained at 25–100 µM should therefore be treated as high-concentration or mechanistic findings rather than directly clinically achievable effects.

Clinical evidence status: Preclinical. Evidence consists primarily of biochemical assays, cancer-cell studies, organoid or stem-like-cell models, and rodent xenograft or genetically engineered tumor models. Combination activity has been reported with cisplatin, paclitaxel, gemcitabine, TRAIL, curcumin, and ionizing radiation, but no convincing randomized human oncology trial or established adjunctive anticancer use was identified. Garcinol is not approved by FDA, Health Canada, or EMA as a cancer therapy.

Safety / deployment status: A standardized 40% garcinol preparation showed low acute and repeated-dose toxicity in rodent studies, including a reported 90-day no-observed-adverse-effect level of 100 mg/kg/day. These data do not establish long-term human safety, reproductive safety, drug-interaction risk, or safety during chemotherapy. Garcinol can inhibit platelet activation experimentally and modulates acetyltransferases and multiple drug-relevant signalling pathways, creating plausible interaction concerns. Hepatotoxicity reports involving multi-ingredient Garcinia cambogia supplements cannot be attributed specifically to purified garcinol.

Garcinol Mechanistic Profile

P: 0–30 min    R: 30 min–3 hr    G: >3 hr